Pharmaceutical companies across the world have been conducting research trials on a daily basis now across the globe to develop vaccines and drugs that can cure coronavirus. In India, the manufacturing of Remdesivir and Favipiravir has commenced, both of which have shown positive results for alleviating the symptoms of COVID-19 patients.
However, the drug potency for both of these drugs for curing infections is debatable and clinical trials are underway. Favipiravir is currently being tested in 18 clinical trials for COVID-19 and results from only two studies have shown a positive outcome but only in COVID cases with mild to moderate symptoms. With respect to Remdesivir, The New England Journal of Medicine said there is a need for more information from ongoing randomized trials to conclude whether the drug alone is sufficient for treatment.
Multiple vaccine candidates are known to be in various stages of trial and given that the world’s fastest vaccine (for mumps) took five years to develop, the proverbial light at the end of the tunnel may not be very visible anytime soon. In the second-most populated country in the world, where existing spaces are confined and thus making it eerily difficult for suspected and positive COVID-19 patients to effectively follow quarantine norms, social distancing, regular hand washing, and wearing masks remains our best bet.
However, as India turns the economy ignition and citizens step out of their homes to resume their lives, the fear of community transmission looms large.This particular aspect has given rise to COVID-19 Insurance and has been known to have help secure a lot of medical funding for the patients.